GT Biopharma (GTBP) Receivables - Net (2013 - 2014)

GT Biopharma (GTBP) posted quarterly Receivables - Net of $5000.0 for Q2 2014, down 83.33% quarter-over-quarter from $30000.0 in Q1 2014.

GT Biopharma (GTBP) Receivables - Net (2013 - 2014) Analysis & Trends

GT Biopharma (GTBP) has reported Receivables - Net for 2 consecutive years, with $5000.0 the latest figure, recorded in Q2 2014.

In Q2 2014, Receivables - Net changed N/A year-over-year to $5000.0; the TTM figure through Jun 2014 stood at $5000.0 (changed N/A YoY), while the FY2013 annual figure was $40000.0, changed N/A from the prior year.
Receivables - Net eased to $5000.0 in Q2 2014 per GTBP's latest filing, from $30000.0 in the prior quarter.
Across five years, Receivables - Net topped out at $40000.0 in Q4 2013 and bottomed at $5000.0 in Q2 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	GT Biopharma	8.64 Mn	8.64 Mn	-

Download Data